GlassScriptPhysician profile
Maureen M Wallace
NPI 1073559399
$2,939.42
in general payments reported to CMS, 2019-2025
33 companies · $1,015 in 2025
The $1,015 reported for 2025 was more than what 81% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $146 · 2022: $22.81 · 2023: $864 · 2024: $892 · 2025: $1,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,501 · Education: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,500.51 |
| Education | $269.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $311.91 | 2023-2025 | Enhertu, Imfinzi |
| Pfizer INC. | $265.00 | 2023-2025 | |
| Incyte Corporation | $244.04 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Astellas Pharma US INC | $170.96 | 2023-2024 | Padcev, Xtandi, Xospata |
| Abbvie INC. | $164.21 | 2023-2025 | |
| Glaxosmithkline, LLC. | $155.11 | 2023-2025 | Ojjaara, Shingrix, Jemperli |
| Celgene Corporation | $150.78 | 2023-2025 | Reblozyl, Pomalyst, Pomalyst |
| Merck Sharp & Dohme LLC | $147.99 | 2023-2025 | Keytruda, Lynparza |
| Sobi, INC | $134.57 | 2023-2025 | |
| Seagen INC. | $126.57 | 2023-2025 | Adcetris |
| Daiichi Sankyo INC. | $116.38 | 2024-2025 | Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $114.59 | 2023-2025 | |
| Janssen Biotech, INC. | $105.43 | 2021-2025 | Imbruvica, Darzalex, Erleada |
| Stemline Therapeutics INC. | $79.37 | 2023-2025 | Orserdu |
| Sanofi-Aventis U.S. LLC | $69.99 | 2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $64.34 | 2023-2024 | |
| Karyopharm Therapeutics INC. | $61.20 | 2024-2025 | Xpovio |
| Pharmacosmos Therapeutics INC. | $50.00 | 2023-2024 | Monoferric |
| Gilead Sciences, INC. | $46.34 | 2023-2025 | Trodelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.05 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $35.86 | 2025 | |
| Eisai INC. | $32.07 | 2024 | |
| Geron Corporation | $30.57 | 2025 | Rytelo |
| Kite Pharma, INC. | $28.34 | 2024 | Yescarta |
| Lilly USA, LLC | $26.81 | 2023 | Verzenio, Retevmo, Jaypirca |
| Beigene USA, INC. | $24.85 | 2024 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $23.24 | 2023 | Libtayo |
| Pharmaessentia USA Corporation | $21.98 | 2025 | Besremi |
| Progenics Pharmaceuticals, INC. | $21.81 | 2024 | |
| Coherus Oncology, INC. | $21.29 | 2024 | |
| Springworks Therapeutics, INC. | $20.05 | 2025 | Ogsiveo |
| Aveo Pharmaceuticals, INC. | $19.55 | 2025 | |
| Emd Serono, INC. | $15.17 | 2023 | Tepmetko |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maureen Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.